## Abstract ## BACKGROUND. An open‐label Phase II study of tipifarnib was conducted to evaluate its safety and efficacy in children with recurrent or refractory medulloblastoma (MB)/primitive neuroectodermal tumor (PNET), high‐grade glioma (HGG), and diffuse intrinsic brainstem glioma (BSG). ## M
✦ LIBER ✦
Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors : A pediatric brain tumor consortium study
✍ Scribed by Maryam Fouladi; Susan M. Blaney; Tina Young Poussaint; Burgess B. Freeman III; Roger McLendon; Christine Fuller; Adekunle M. Adesina; Michael L. Hancock; Mary K. Danks; Clinton Stewart; James M. Boyett; Amar Gajjar
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 105 KB
- Volume
- 107
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
A phase II study of the farnesyl transfe
✍
Maryam Fouladi; H. Stacy Nicholson; Tianni Zhou; Fred Laningham; Kathleen J. Hel
📂
Article
📅
2007
🏛
John Wiley and Sons
🌐
English
⚖ 97 KB
👁 2 views
Hyperthermia for the treatment of patien
✍
Rüdiger Wessalowski; Heidi Kruck; Hildegard Pape; Thomas Kahn; Reinhart Willers;
📂
Article
📅
1998
🏛
John Wiley and Sons
🌐
English
⚖ 151 KB
👁 3 views
waves in combination with platinum-based chemotherapy in ten children and 4 Institute of Statistics, Heinrich-Heine Univeradolescents with recurrent or refractory GCTs. sity, Du ¨sseldorf, Germany. ## RESULTS. Seven of ten patients with recurrent or refractory GCTs had objective responses. Of the